Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients
Georgina Maalouf, Anaïs Andrillon, Mathilde Leclercq, P. Sève, P. Bielefeld, J. Gueudry, Thomas Sené, Chérif Titah, T. Moulinet, Bénédicte Rouvière, D. Sène, A.C. Desbois, F. Domont, Sara Touhami, Thomas Thibault, Carolla El Chamieh, P. Cacoub, Laurent Kodjikian, Lucie Biard, Bahram Bodaghi, David Saadoun
Topics & Concepts
MedicineAdalimumabInfliximabUveitisHazard ratioInterquartile rangeInternal medicineRetinal vasculitisRetrospective cohort studyOdds ratioEtanerceptSurgeryPrednisoneGastroenterologyMacular edemaRheumatoid arthritisVasculitisDiseaseVisual acuityConfidence intervalOphthalmologyOcular Diseases and Behçet’s SyndromeSarcoidosis and Beryllium Toxicity ResearchOtitis Media and Relapsing Polychondritis